BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 15, 2024
See today's BioWorld MedTech
Home
» Funding Challenges Explored: Series B round becoming the new A round as early stage funding thins
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Funding Challenges Explored: Series B round becoming the new A round as early stage funding thins
Feb. 10, 2014
By
Omar Ford
No Comments
In 2012, during a panel at the Southeastern Medical Device Association (SEMDA; Norcross, Georgia) med-tech serial entrepreneur Jerry Gibson uttered the unforgettable phrase that today's "A-round funding is yesterday's B-round funding."
BioWorld MedTech
